KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)
Stock Stats
News
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form 424B3 KAZIA THERAPEUTICS LTD
Form 424B3 KAZIA THERAPEUTICS LTD
Form 424B3 KAZIA THERAPEUTICS LTD
Form 424B3 KAZIA THERAPEUTICS LTD
Form 6-K KAZIA THERAPEUTICS LTD For: Jan 27
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.